Canagliflozin, another Sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been demonstrated to decrease the risk of renal failure progression by ameliorating intraglomerular hypertension, offering a protective stance for renal microvasculature [25,26]. This evidence concerns the gene SLC5A2 and Hypertension.